Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$271.19−0.54 (-0.20%)
Close on Nov 17, 2026Market cap $16.81BP/E 22.3Yield –
Ascendis Pharma A/S revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ascendis Pharma A/S's revenue for the twelve months ending Jun 30, 2026 was €1.05B, up 113.4% year over year. For fiscal 2025 it was €720.13M, up 98.0% from the year before. Over ten years it grew 56.6% a year on average. The highest annual figure on record is €720.13M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €720.13M | +98.0% |
| FY2024 | Dec 31, 2024 | €363.64M | +36.3% |
| FY2023 | Dec 31, 2023 | €266.72M | +421.2% |
| FY2022 | Dec 31, 2022 | €51.17M | +557.9% |
| FY2021 | Dec 31, 2021 | €7.78M | +11.9% |
| FY2020 | Dec 31, 2020 | €6.95M | -48.0% |
| FY2019 | Dec 31, 2019 | €13.38M | +26.4% |
| FY2018 | Dec 31, 2018 | €10.58M | +591.6% |
| FY2017 | Dec 31, 2017 | €1.53M | -66.8% |
| FY2016 | Dec 31, 2016 | €4.61M | -43.3% |
| FY2015 | Dec 31, 2015 | €8.12M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €339.29M | +114.7% |
| Q1 FY2026 | Mar 31, 2026 | €246.60M | +144.3% |
| Q4 FY2025 | Dec 31, 2025 | €247.50M | +42.3% |
| Q3 FY2025 | Sep 30, 2025 | €213.63M | +269.4% |
| Q2 FY2025 | Jun 30, 2025 | €158.05M | +339.0% |
| Q1 FY2025 | Mar 31, 2025 | €100.95M | +5.3% |
| Q4 FY2024 | Dec 31, 2024 | €173.92M | +26.3% |
| Q3 FY2024 | Sep 30, 2024 | €57.83M | +20.4% |
| Q2 FY2024 | Jun 30, 2024 | €36.00M | -24.0% |
| Q1 FY2024 | Mar 31, 2024 | €95.89M | +185.5% |
| Q4 FY2023 | Dec 31, 2023 | €137.70M | +501.4% |
| Q3 FY2023 | Sep 30, 2023 | €48.03M | +214.2% |
| Q2 FY2023 | Jun 30, 2023 | €47.39M | +669.4% |
| Q1 FY2023 | Mar 31, 2023 | €33.59M | +391.9% |
| Q4 FY2022 | Dec 31, 2022 | €22.90M | +367.6% |
| Q3 FY2022 | Sep 30, 2022 | €15.29M | +1273.8% |
| Q2 FY2022 | Jun 30, 2022 | €6.16M | +502.7% |
| Q1 FY2022 | Mar 31, 2022 | €6.83M | +815.3% |
| Q4 FY2021 | Dec 31, 2021 | €4.90M | +815.3% |
| Q3 FY2021 | Sep 30, 2021 | €1.11M | -59.6% |
| Q2 FY2021 | Jun 30, 2021 | €1.02M | -28.8% |
| Q1 FY2021 | Mar 31, 2021 | €746.00K | -66.5% |
| Q4 FY2020 | Dec 31, 2020 | €535.00K | -78.7% |
| Q3 FY2020 | Sep 30, 2020 | €2.76M | +22.9% |
| Q2 FY2020 | Jun 30, 2020 | €1.44M | -55.3% |
| Q1 FY2020 | Mar 31, 2020 | €2.23M | -58.9% |
| Q4 FY2019 | Dec 31, 2019 | €2.51M | -76.2% |
| Q3 FY2019 | Sep 30, 2019 | €2.24M | +11115.0% |
| Q2 FY2019 | Jun 30, 2019 | €3.21M | +17738.9% |
| Q1 FY2019 | Mar 31, 2019 | €5.41M | +19235.7% |
| Q4 FY2018 | Dec 31, 2018 | €10.52M | +3655.4% |
| Q3 FY2018 | Sep 30, 2018 | €20.00K | -95.4% |
| Q2 FY2018 | Jun 30, 2018 | €18.00K | -95.9% |
| Q1 FY2018 | Mar 31, 2018 | €28.00K | -92.5% |
| Q4 FY2017 | Dec 31, 2017 | €280.00K | – |
| Q3 FY2017 | Sep 30, 2017 | €434.00K | – |
| Q2 FY2017 | Jun 30, 2017 | €444.00K | – |
| Q1 FY2017 | Mar 31, 2017 | €372.00K | – |
See a number that looks wrong?